Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia · Delayed Price · Currency is AUD 3.650
-0.110 (-2.93%)
Feb 26, 2026, 2:19 PM AEST
Clarity Pharmaceuticals Revenue
In the fiscal year ending June 30, 2025, Clarity Pharmaceuticals had annual revenue of 9.46M AUD, down -17.76%. Clarity Pharmaceuticals had revenue of 4.77M in the half year ending June 30, 2025, with 17.37% growth.
Revenue
9.46M
Revenue Growth
-17.76%
P/S Ratio
147.82
Revenue / Employee
137.14K
Employees
69
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 9.46M | -2.04M | -17.76% |
| Jun 30, 2024 | 11.51M | 1.71M | 17.41% |
| Jun 30, 2023 | 9.80M | 3.34M | 51.74% |
| Jun 30, 2022 | 6.46M | 3.26M | 102.06% |
| Jun 30, 2021 | 3.20M | 407.65K | 14.62% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 1.21B |
| Neuren Pharmaceuticals | 218.86M |
| Clinuvel Pharmaceuticals | 95.02M |
| Mesoblast | 26.23M |
| PYC Therapeutics | 20.56M |
| Orthocell | 9.33M |
| Immutep | 6.38M |
| Racura Oncology | 6.04M |